Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2019, Issue 2


Bozada-Gutiérrez KE, Fresán-Orellana A, Yamamoto-Furusho JK
Validación de Belief Medicines Questionnaire y Self-efficacy for Appropriate Medication Use Scale para medir adherencia al tratamiento farmacológico en pacientes con enfermedad inflamatoria intestinal
Gac Med Mex 2019; 155 (2)

Language: Español
References: 29
Page: 124-129
PDF: 234.52 Kb.


Full text




ABSTRACT

Introduction: Treatment adherence is crucial in inflammatory bowel disease (IBD) to prevent relapses and complications. In Mexico, there is not a validated tool to assess adherence in patients with IBD. Objective: To translate the beliefs about medicines questionnaire (BMQ) and self-efficacy for appropriate medication use scale (SEAMS) instruments, as well as to determine their validity, reliability and sensitivity in IBD-diagnosed Mexican patients. Method: After informed consent was obtained, 149 IBD-diagnosed patients were included. The instruments were translated into Spanish and were subsequently applied during medical consultation. For SEAMS, exploratory factorial analysis and ROC curve analysis were carried out and Cronbach’s alpha was determined; for the BMQ, Cohen’s kappa coefficient and its predictive capacity were employed. Results: Seventy- five women (50.3%) were included, with an average age of 44 years. The SEAMS scale showed a single factor that was highly reliable (Cronbach’s alpha = 0.92) and a cutoff point of 33 to identify adherent patients. The “adherence” and “recall barrier” dimensions of the BMQ were adequate adherence predictors. Conclusions: The SEAMS and BMQ Spanish versions are valid for measuring self-efficacy and barriers to pharmacological treatment adherence in Mexican patients with IBD.


Key words: Adherence, Self-efficacy, Barriers, Pharmacological treatment, Inflammatory bowel disease.


REFERENCIAS

  1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361 2066-2078.

  2. Sabaté E. Adherence to long-term therapies: evidence for action. Suiza: World Health Organization; 2003.

  3. Mårdby AC, Åkerlind I, Jörgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns. 2007; 69:158-164.

  4. Kane S V, Robinson A. Understanding adherence to medication in ulcerative colitis–innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010;32:1051-1058.

  5. Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012;12:132.

  6. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Ther. 2009;26:936-946.

  7. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247-257.

  8. Van Staa TP, Card T, Logan RF, Leufkens HG. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.

  9. Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel‐Wood M. Longterm oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755-764.

  10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.

  11. Nguyen TMU, La-Caze A, Cottrell N. What are validated self-report adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77:427-445.

  12. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986: 24:67-74.

  13. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Heal. 2002;17:17-32.

  14. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Heal. 1999;14:1-24.

  15. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. 2007;15 203-219.

  16. Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982;37:122.

  17. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med. 1997;19:239-263.

  18. Perpiñá-Tordera M, Martínez-Moragón EM, Belloch-Fuster A, Lloris- Bayo A, Pellicer-Císcar C. Spanish asthma patients’ beliefs about health and medicines: validation of 2 questionnaires. Arch Bronconeumol. 2009; 45:218-223.

  19. Fall E, Gauchet A, Izaute M, Horne R, Chakroun N. Validation of the French version of the Beliefs about Medicines Questionnaire (BMQ) among diabetes and HIV patients. Rev Eur Psychol Appliquée/European Rev Appl Psychol. 2014;64 335-343.

  20. Jónsdóttir H, Friis S, Horne R, Pettersen KI, Reikvam Å, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009; 119:78-84.

  21. Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford). 2005; 44:762-767.

  22. Horne R, Parham R, Driscoll R, Robinson A. Patient’s attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:837-844.

  23. Pan Y, De la Puente M. Census bureau guideline for the translation of data collection instruments and supporting materials: documentation on how the guideline was developed. Surv Methodol. 2005;6.

  24. Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2014;54:494-499.

  25. Giordano TP, Guzmán D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.

  26. Pedrosa RB, Rodrigues RC, Oliveira HC, Alexandre NM. Construct validity of the Brazilian version of the Self-Efficacy for Appropriate Medication Adherence Scale. J Nurs Meas. 2016;24:18-31.

  27. Dong XF, Liu YJ, Wang AX, Lv PH. Psychometric properties of the Chinese version of the Self-Efficacy for Appropriate Medication Use Scale in patients with stroke. Patient Prefer Adherence. 2016;10:321-327.

  28. Michetti P, Weinman J, Mrowietz U, Smolen J, Louis E, Peyrin-Biroulet L, et al. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study. Adv Ther. 2017;34:91-108.

  29. De Castro ML, Sanromán L, Martín A, Martínez N, Hernández V, Del Campo V, et al. Valoración de la adhesión terapéutica en la enfermedad inflamatoria intestinal. Comparación entre una escala de autoevaluación y un índice farmacéutico de dispensación de medicamentos. Rev Esp Enferm Dig. 2017;109 542-551.






>Journals >Gaceta Médica de México >Year 2019, Issue 2
 

· Journal Index 
· Links 






       
Copyright 2019